Table 1.
Baseline subject characteristics stratified by glucose tolerance status
| Normal Glucose Tolerance (N=35) |
Impaired Glucose Tolerance (N=25) |
|
|---|---|---|
| Race (% Caucasian) | 69% | 56% |
| Age (years) | 58 ± 1 | 63 ± 1** |
| Weight (kg) | 86 ± 2 | 91 ± 3 |
| BMI (kg/m2) | 32 ± 1 | 35 ± 1 |
| Waist circumference (cm) | 94 ± 2 | 103 ± 3** |
| Hip circumference (cm) | 117 ± 2 | 122 ± 3 |
| Waist to hip ratio | 0.80 ± 0.01 | 0.85 ± 0.01** |
| Body fat (%) | 47 ± 1 | 49 ± 1 |
| Total body fat mass (kg) | 41 ± 2 | 45 ± 2 |
| Total body fat-free mass (kg) | 46 ± 1 | 47 ± 1 |
| Android fat mass (kg) | 3.4 ± 0.2 | 4.0 ± 0.2* |
| Gynoid fat mass (kg) | 7.6 ± 0.3 | 7.8 ± 0.4 |
| Android/gynoid fat mass | 0.44 ± 0.01 | 0.49 ± 0.01** |
| Visceral abdominal fat area (cm2) | 137 ± 11 | 175 ± 16 |
| Subcutaneous abdominal fat area (cm2) | 446 ± 28 | 426 ± 31 |
| Visceral/subcutaneous abdominal fat ratio | 0.31 ± 0.03 | 0.44 ± 0.05** |
| Abdominal FCW (μg triglyceride/cell) | 0.56 ± 0.02 | 0.61 ± 0.03** |
| Gluteal FCW (μg triglyceride/cell) | 0.62 ± 0.02 | 0.66 ± 0.02 |
| Abdominal/gluteal FCW | 0.91 ± 0.02 | 0.95 ± 0.03 |
| Absolute VO2max (L/min) | 1.7 ± 0.1 | 1.5 ± 0.1 |
| Relative VO2max (mL/kg/min) | 20.3 ± 0.8 | 16.7 ± 0.9** |
Significantly different from NGT:
*
P<0.05,
**
P<0.01